Integrating drug discovery R&D
Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses how integrating processes could help streamline drug discovery in the future.
List view / Grid view
Articles
Expert view: Bio-Rad’s comprehensive genomics portfolio provides answers for every problem
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
Getting connected – the key to solving the reproducibility problem?
As technology advances and scientific research progresses at a rapid pace, data is being generated in ever-larger quantities. Even with the forward strides in technology and advances in data processing, a common problem widely acknowledged by the scientific community is that of reproducibility. In this article, Matjaz Hren discusses the…
Expert view: Opportunities in flow cytometry
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
Expert view: The importance of accurate synthetic DNA fragments
Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.
Expert view: Advancing antibody discovery with picodroplet technology
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
Expert view: Engineered antibodies: semi-rational design approach for faster optimisation
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
Expert view: Call to action: establishing the protein-binding properties of oligonucleotides
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
Expert view: Clarification of cell cultures without centrifugation
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
Upstream Bioprocessing In-Depth Focus 2019
This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in upstream bioprocessing.
Antibodies In-Depth Focus 2019
The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this area of medicine to identify drug targets.
Genomics In-Depth Focus 2019
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
Drug Target Review – Issue 3 2019
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Five recent Parkinson’s disease drug target discoveries
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
The promise and pitfalls of serial femtosecond X-ray crystallography
A report from scientists at the Moscow Institute of Physics and Technology highlights the advantages and disadvantages of serial femtosecond X-ray crystallography. This article investigates the review, focusing on its role in drug development.